Rational psychopharmacology for patients with HIV infection and AIDS

Psychiatric Annals

Volumn 31, Issue 1, 2001, Pages 28-34

  Gillenwater, David R ^a   McDaniel, J Stephen ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23044521479     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20010101-08     Document Type: Article

References (25)

1. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338: 1281-1292.
2. Chuck SK, Rodvold KA, von Moltke LL, Greenblatt DJ, Shader RI. Pharmacokinetics of protease inhibitors and drug interactions with psychoactive drugs. In: Ostrow D, Kalichman SC, eds. Psychological and Public Health Implications of New HIV Therapies. New York: Plenum Press; 1998:30-60.
3. Pies R. Antimicrobials in psychiatry. Psychiatric Times. March 1999:32-33.
4. Fahey JL, Flemming DS, eds. AIDS/HIV Reference Guide for Medical Professionals, 4th ed. Los Angeles: Williams and Wilkins; 1997:361-372.
5. Chang GWM, Kam PCA. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia. 1999;54:42-50.
6. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc. 1997;72:835-847.
7. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
8. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry. 1998;59(suppl 15):19-27.
9. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998;38: 106-111.
10. Amprenavir: a new HIV protease inhibitor. The Medical Letter. 1999;41:64-66.
11. Holzer C, Coleman R. HIV therapy: drug interactions. Available at: www.hivinsite.ucsf.edu/topics/ research_advances/2098.339b.html.
12. Preston SL, Stein DS. Drug interactions and adverse drug reactions with protease inhibitors. Primary Psychiatry. July 1997:64-69.
13. Mechcatie E. Orap manufacturer warns of sudden deaths. Clinical Psychiatry News. November 1999:4.
14. Montero A, Giovannoni AG, Tvrde PL. Leg ischemia in a patient receiving ritonavir and ergotamine. Ann Intern Med. 1999;130:329-330.
15. Nandwani R, Gourlay Y. Possible interaction between sildenafil and HIV combination therapy. Lancet. 1999;353:840.
16. Merry C, Mulcahy F, Barry M, Gibbons S, Back D. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. AIDS. 1997;11:268-269.
17. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol. 1999;19:293-296.
18. Akula SK, Rege AB, Dreisbach AW, Dejace PM, Lertora JJ. Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. Am J Med Sci. 1997;313:244-246.
19. Eskalith [product monograph]. Philadelphia, PA: SmithKline Beecham Pharmaceuticals; 1999.
20. Neurontin [product monograph]. Morris Plains, NJ: Parke-Davis Pharmaceuticals; 1998.
21. Lamictal [product monograph]. Research Triangle Park, NC: Glaxo Wellcome Inc.; 1999.
22. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology. 1999;91:681-685.
23. Demerol (meperidine) [product monograph]. New York: Sanofi Pharmaceuticals; 1998.
24. Methylin (methylphenidate) [product monograph]. St. Louis, MO: Mallinckrodt Inc; 1999.
25. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet. 1998;352:1751-1752.